Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
David Thomson, Executive Vice President, General Counsel, and Secretary at MannKind Corp (NASDAQ:MNKD), recently executed several stock transactions as reported in an SEC filing. Notably, Thomson sold 32,179 shares on May 13, 2025, at a weighted average price of $4.68, totaling $150,597. The sale was conducted under a pre-established Rule 10B5-1 plan. The transaction comes as MannKind trades near its 52-week low of $4.34, though analysts maintain a strong buy consensus with price targets ranging from $9 to $12.
In addition to the sales, Thomson acquired shares through restricted stock unit awards. On May 10, 2025, he acquired 105,600 shares, and on May 13, 2025, he acquired another 119,000 shares, both at no cost. Additionally, he received 145,000 performance-based restricted stock units on May 13, 2025, also at no cost. According to InvestingPro, MannKind demonstrates strong financial health with a "GREAT" overall rating and impressive revenue growth of 32.5% over the last twelve months.
Thomson’s transactions reflect a mix of strategic sales and acquisitions, as he continues to hold a substantial number of shares in MannKind Corp. For deeper insights into insider trading patterns and comprehensive financial analysis, explore MannKind’s detailed Pro Research Report, available exclusively on InvestingPro.
In other recent news, MannKind Corporation reported its first-quarter 2025 financial results, showcasing a mixed performance. The company’s revenue exceeded expectations, reaching $78.35 million, marking an 18% year-over-year increase, while earnings per share (EPS) came in slightly below forecasts at $0.04. This revenue growth was largely driven by a 32% increase in Tyvaso DPI royalties and an 18% rise in collaboration and services revenue. Despite the positive revenue figures, the company’s stock reacted negatively, which could be attributed to the EPS miss. MannKind also announced the departure of its Chief Medical (TASE:BLWV) Officer, Burkhard Blank, with a transition plan set for his exit by August 2025. The company has entered a transition and separation agreement with Blank, who will continue as a non-executive employee until his departure. Additionally, MannKind is preparing for the potential approval of pediatric Afrezza and anticipates continued growth in Tyvaso DPI royalties. Investors should note that these developments are part of MannKind’s ongoing strategic initiatives and pipeline advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.